Extensive experimental trials on benchmark instances demonstrate a significant decrease in instance size for certain classes of problems.
Enterprises should create an AR strategy in the business, with specific goals and tasks for trials and benchmarks.
It is noteworthy that there is an overall methodological difference between experimental trials and benchmarking trials.
Very few randomized, controlled trials of benchmarking for type 2 diabetes in primary care have been reported, and the effectiveness of this approach is as yet undetermined (12– 12).
Testing and validating these markers in clinical trials and benchmarking against established strategies will be crucial in order to improve disease outcome.
Furthermore the randomised double-blinded placebo-controlled Phase III trial, the benchmark of traditional small molecule development, is not feasible for ATMPs especially as many are in the field of rare diseases.
There are several benchmark trials to suggest that multicentre trials are not only feasible, but should be the current norm.
This improvement is consistent with the results of a small randomized, controlled trial of benchmarking in diabetes primary care (12).
This has been verified by a great number of trials on various benchmark systems in our tests.
For intervention trials and for benchmarking, the starting point should be either the ICU admission or syndrome/disease diagnosis.
